These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12427803)

  • 1. Non-alcoholic steatohepatitis (NASH): why biopsy?
    McNair A
    Gut; 2002 Dec; 51(6):898; author reply 898-9. PubMed ID: 12427803
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the non-alcoholic fatty liver disease activity score.
    Hjelkrem M; Stauch C; Shaw J; Harrison SA
    Aliment Pharmacol Ther; 2011 Jul; 34(2):214-8. PubMed ID: 21585409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course.
    Cortez-Pinto H; Camilo ME
    Best Pract Res Clin Gastroenterol; 2004 Dec; 18(6):1089-104. PubMed ID: 15561640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
    J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive and non-invasive investigations for non-alcoholic steatohepatitis (NASH): the need for biochemical markers.
    Ahmed MH
    Scand J Gastroenterol; 2006 Mar; 41(3):372. PubMed ID: 16497631
    [No Abstract]   [Full Text] [Related]  

  • 7. Recommendations for liver biopsy evaluation in non-alcoholic fatty liver disease.
    Stinton LM; Loomba R
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):5-13. PubMed ID: 24632764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic criteria for non-alcoholic steatohepatitis].
    Hashimoto E
    Nihon Rinsho; 2006 Jun; 64(6):1025-32. PubMed ID: 16768105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transitional features of histologic type of non-alcoholic fatty liver disease in Korean young men.
    Kim JK; Chon NR; Lim HC; Lee KS; Han KH; Chon CY; Park YN; Paik YH
    J Gastroenterol Hepatol; 2012 Jan; 27(1):142-8. PubMed ID: 21883454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of nonalcoholic from alcoholic steatohepatitis: are routine laboratory markers useful?
    Kazemi-Shirazi L; Veloso MP; Frommlet F; Steindl-Munda P; Wrba F; Zehetmayer S; Marsik C; Ferenci P
    Wien Klin Wochenschr; 2008; 120(1-2):25-30. PubMed ID: 18239988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?
    Cengiz M; Candır BA; Yılmaz G; Akyol G; Ozenirler S
    World J Gastroenterol; 2013 Nov; 19(42):7412-8. PubMed ID: 24259972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease.
    Tannapfel A; Denk H; Dienes HP; Langner C; Schirmacher P; Trauner M; Flott-Rahmel B
    Virchows Arch; 2011 May; 458(5):511-23. PubMed ID: 21442288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathology and biopsy assessment of non-alcoholic fatty liver disease.
    Straub BK; Schirmacher P
    Dig Dis; 2010; 28(1):197-202. PubMed ID: 20460911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Histopathological diagnose of non-alcoholic and alcoholic fatty liver disease].
    Tannapfel A; Denk H; Dienes HP; Langner C; Schirmacher P; Trauner M; Flott-Rahmel B
    Z Gastroenterol; 2010 Apr; 48(4):486-98. PubMed ID: 20352596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
    Ito S; Yukawa T; Uetake S; Yamauchi M
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will non-invasive testing replace liver biopsy in the diagnosis and follow-up of non-alcoholic steatohepatitis (NASH)?
    Romero FP
    Rev Esp Enferm Dig; 2009 Aug; 101(8):521-7. PubMed ID: 19785490
    [No Abstract]   [Full Text] [Related]  

  • 18. Non-alcoholic steatohepatitis with normal aminotransferase values.
    Uslusoy HS; Nak SG; Gülten M; Biyikli Z
    World J Gastroenterol; 2009 Apr; 15(15):1863-8. PubMed ID: 19370784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD).
    Bellentani S; Marino M
    Ann Hepatol; 2009; 8 Suppl 1():S4-8. PubMed ID: 19381118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.